New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export KARD’s income statement to Excel — free account
KARDIGAN INC
KARD- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
11.54
0.98
−7.83%
After hours trading: 11.54, unchanged, last trade Fri 4:01pm Eastern.
Follow KARD
Alert me
Analysts’ price targets Wall Street, collected weekly
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 1 | +66.7% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | (89) | (196) | (288) | n/m | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Net income | — | — | — | — | — | — | — | — | (89) | (192) | (287) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| Earnings | — | — | — | — | — | — | — | — | (8.79) | (14.84) | (13.33) | n/m | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (1.87) | (11.68) | (2.38) | n/m | ||||||
| Capex | — | — | — | — | — | — | — | — | (0.18) | (0.40) | (0.09) | +122.1% | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (2.05) | (12.07) | (2.46) | n/m | ||||||
| Book value | — | — | — | — | — | — | — | — | (8.25) | (19.35) | 6.22 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 10 | 13 | 36 | +28.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | n/m | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (19) | (151) | (219) | n/m | |||||
| Capex | — | — | — | — | — | — | — | — | (2) | (5) | (8) | +184.9% | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (21) | (156) | (227) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 42 | 308 | 439 | +632.3% | |||||
| Net debt | — | — | — | — | — | — | — | — | (49) | (335) | (472) | n/m | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (83) | (250) | 573 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | — | (84.47) | (80.59) | — | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | 0.00 | (187.24) | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | — | — | 115.10 | (117.38) | — | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 241 | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Negative figures in brackets.
estimates
Fundamentals updated Nov 18, 2026
KARDIGAN INC vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MLYS Mineralys Therapeutics, Inc. | $1.3B | — (loss-making) | — | — | n/m | −49.27% (below 0%: shrinking) | — | — | Compare |
| SLN Silence Therapeutics PLC Sponsored ADR | $1.2B | — (loss-making) | — (loss-making) | +197.18% (above 0%: growing) | n/m | −17.28% (below 0%: shrinking) | 97.39% | (3,729.15%) | Compare |
| GPCR Structure Therapeutics Inc. Sponsored ADR | $1.2B | — (loss-making) | — | — | n/m | −100.40% (below 0%: shrinking) | 0.00% | — | Compare |
| SVRA Savara Inc. | $1.2B | — (loss-making) | — (loss-making) | — | n/m | −90.03% (below 0%: shrinking) | 0.00% | (1,301,100.00%) | Compare |
| KARD KARDIGAN INC | $1.2B | — (loss-making) | — | — | n/m | −28.61% (below 0%: shrinking) | — | — | |
| AAPG Ascentage Pharma Group International - Unsponsored ADR | $1.2B | — | — | — | — | — | — | — | Compare |
| VOR Vor Biopharma Inc. | $1.1B | — (loss-making) | — | — | n/m | −47.59% (below 0%: shrinking) | — | — | Compare |
| NKTR Nektar Therapeutics | $1.1B | — (loss-making) | — (loss-making) | −20.39% (below 0%: shrinking) | n/m | −47.99% (below 0%: shrinking) | 100.00% | (615.83%) | Compare |
| INBX Inhibrx Biosciences, Inc. | $1.1B | — (loss-making) | — (loss-making) | — | n/m | −2.29% (below 0%: shrinking) | 100.00% | (1,586.75%) | Compare |
| Median of peers | $1.2B | — | — | — | — | −47.99% | 97.39% | (2,657.95%) |
KARDIGAN INC (KARD) Latest News
What happened
- Results Kardigan reported a third-quarter net loss of $58.6 million, or 64 cents per share, and $591.4 million in cash and investments.
- Other Kardigan completed enrollment of 156 participants and set the trial’s primary endpoint assessment at Week 48, with topline results expected in the second half of 2027.
- Kardigan Announces Appointment of Kristin Reinke to its Board of Directors Business Wire
- Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
- Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
- Kardigan shares soar after Nasdaq debut
- Kardigan Announces Pricing of Upsized Initial Public Offering